Proteogenomic characterization unveils biomarkers associated with chemoresistance in muscle-invasive bladder cancer

蛋白质基因组学特征分析揭示了与肌层浸润性膀胱癌化疗耐药相关的生物标志物

阅读:10
作者:Matthew V Holt ,Yongchao Dou ,Meggie N Young ,Alexander B Saltzman ,Meenakshi Anurag ,Jonathan T Lei ,Antrix Jain ,Mei Leng ,Beom-Jun Kim ,Lacey E Dobrolecki ,Stefanie F Faucher ,Sara Savage ,Chenwei Wang ,Zhiao Shi ,Hugo Villanueva ,Karoline Kremers ,Kyle D Drinnon ,Patricia D Castro ,Michael M Ittmann ,Mehak Mehboob Khatani ,Sung Han Kim ,Matthew J Ellis ,Bing Zhang ,Anna Malovannaya ,Seth P Lerner

Abstract

To explore potential chemoresistance mechanisms and identify therapeutic opportunities in muscle-invasive bladder cancer (MIBC), we conduct comprehensive proteogenomic characterization of 46 pre- and 14 post-treatment MIBC tumors incorporating genomics, transcriptomics, proteomics, and phosphoproteomics. Multi-omics clustering not only recapitulated established molecular subtypes but also revealed subtypes associated with chemotherapy sensitivity. Protein isoform level analysis identifies protein abundance of a short isoform of ATAD1 and RAF family proteins as biomarkers of chemosensitivity. Integration of proteomic and phosphoproteomic data reveals Wnt signaling via GSK3B-S9 phosphorylation and the JAK/STAT pathway as potential targets to overcome chemoresistance. Correlations between PD-L1 and TROP-2/NECTIN-4 indicate an additive benefit of combination therapy targeting these proteins. Overall, this study serves as a valuable resource for researchers and clinicians aiming to better understand and treat chemoresistant MIBC. Keywords: GSK3B; RAF family; STAT3; biomarkers; chemoresistance; muscle-invasive bladder cancer; proteogenomics.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。